Veliparib

Generic Name: Veliparib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₆N_₄O

CAS Number: 912444-00-9

Unique Ingredient Identifier: 01O4K0631N

Indication: 与化疗药物紫杉醇和卡铂联合用于治疗乳腺癌。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Completed

Conditions: Fallopian Tube Carcinoma
Fallopian Tube Carcinosarcoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma
Primary Peritoneal Serous Adenocarcinoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Veliparib

First Posted Date: 2009-10-05

Last Posted Date: 2021-10-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 431

Registration Number: NCT00989651

Locations: 🇺🇸
MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 20 locations

ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors

Phase 1

Completed

Conditions: Childhood Craniopharyngioma
Childhood Grade I Meningioma
Childhood Mixed Glioma
Childhood Supratentorial Ependymoma
Recurrent Childhood Brain Tumor
Recurrent Childhood Spinal Cord Neoplasm
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Childhood Grade II Meningioma
Childhood Low-grade Cerebellar Astrocytoma
Childhood Low-grade Cerebral Astrocytoma

Interventions: Drug: veliparib
Drug: temozolomide
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2009-07-27

Last Posted Date: 2014-07-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00946335

Locations: 🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Phase 1

Completed

Conditions: BRCA1 Mutation Carrier
Breast Carcinoma
Estrogen Receptor Negative
HER2/Neu Negative
Hereditary Breast and Ovarian Cancer Syndrome
Basal-Like Breast Carcinoma
Progesterone Receptor Negative
Solid Neoplasm
BRCA2 Mutation Carrier
Ovarian Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2009-05-04

Last Posted Date: 2018-06-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 98

Registration Number: NCT00892736

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
City of Hope South Pasadena, South Pasadena, California, United States

and more 4 locations

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: temozolomide
Drug: veliparib
Genetic: DNA methylation analysis
Genetic: gene expression analysis
Genetic: mutation analysis
Genetic: proteomic profiling
Other: high performance liquid chromatography
Other: immunoenzyme technique
Other: laboratory biomarker analysis
Other: mass spectrometry
Other: pharmacogenomic studies
Other: pharmacological study
Procedure: adjuvant therapy
Radiation: radiation therapy

First Posted Date: 2008-10-10

Last Posted Date: 2018-06-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 24

Registration Number: NCT00770471

Locations: 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States

and more 8 locations

Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Solid Neoplasm
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2008-08-25

Last Posted Date: 2024-10-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 81

Registration Number: NCT00740805

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Phase 1

Active, not recruiting

Conditions: Adult Acute Megakaryoblastic Leukemia
Adult Acute Monoblastic Leukemia
Adult Acute Monocytic Leukemia
Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With Maturation
Adult Acute Myeloid Leukemia With Minimal Differentiation
Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11
Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A
Adult Acute Myeloid Leukemia Without Maturation

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Topotecan Hydrochloride
Drug: Veliparib

First Posted Date: 2008-01-09

Last Posted Date: 2024-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00588991

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Stage III Lung Cancer AJCC v7
Stage IIIA Ovarian Cancer AJCC v6 and v7
Hodgkin Lymphoma
Metastatic Malignant Neoplasm
Stage IIIC Colon Cancer AJCC v7
Stage IIIC Ovarian Cancer AJCC v6 and v7
Stage IV Breast Cancer AJCC v6 and v7
Stage IV Colon Cancer AJCC v7
Stage IV Lung Cancer AJCC v7
Stage IV Ovarian Cancer AJCC v6 and v7

Interventions: Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2007-12-19

Last Posted Date: 2023-02-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00576654

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Yale University, New Haven, Connecticut, United States

and more 2 locations

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase 1

Completed

Conditions: Adult Solid Neoplasm
BRCA1 Mutation Carrier
BRCA2 Mutation Carrier
Hereditary Breast and Ovarian Cancer Syndrome

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2007-09-26

Last Posted Date: 2015-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 107

Registration Number: NCT00535119

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 4 locations

ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer

Phase 1

Completed

Conditions: Leukemia
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2006-10-13

Last Posted Date: 2012-03-15

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 23

Registration Number: NCT00387608

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy